|
|
||||||||


Departments of
*
Analytical Chemistry,
Immunology,
QC Clinical Development,
§
BioAnalytical Technology, and
¶
Protein Engineering, Genentech, South San Francisco, CA 94080
Rituxan (Rituximab) is a chimeric mAb with human IgG1 constant domains used in the therapy of non-Hodgkins B cell lymphomas. This Ab targets B cells by binding to the cell-surface receptor, CD20. In our investigation of the mechanism of B cell depletion mediated by Rituximab, we first constructed mutants of Rituximab defective in complement activation but with all other effector functions intact. Our results demonstrate that the previously described C1q binding motif in murine IgG2b constituting residues E318, K320, and K322 is not applicable to a human IgG1 when challenged with either human, rabbit, or guinea pig complement. Alanine substitution at positions E318 and K320 in Rituximab had little or no effect on C1q binding and complement activation, whereas alanine substitution at positions D270, K322, P329, and P331 significantly reduced the ability of Rituximab to bind C1q and activate complement. We have also observed that concentrations of complement approaching physiological levels are able to rescue >60% of the activity of these mutant Abs with low affinity for C1q. These data localize the C1q binding epicenter on human IgG1 and suggest that there are species-specific differences in the C1q binding site of Igs.
This article has been cited by other articles:
![]() |
A. W. Pawluczkowycz, F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. J. van de Winkel, P. W. H. I. Parren, and R. P. Taylor Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX J. Immunol., July 1, 2009; 183(1): 749 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Flobakk, I. B. Rasmussen, E. Lunde, T. Frigstad, G. Berntzen, T. E. Michaelsen, B. Bogen, and I. Sandlie Processing of an Antigenic Sequence from IgG Constant Domains for Presentation by MHC Class II J. Immunol., November 15, 2008; 181(10): 7062 - 7072. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Beurskens, S. R. Ruuls, P. J. Engelberts, T. Vink, W. J. Mackus, J. G. J. van de Winkel, and P. W. H. I. Parren Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies Blood, November 15, 2008; 112(10): 4354 - 4355. [Full Text] [PDF] |
||||
![]() |
S. A. Beers, M. S. Cragg, and M. J. Glennie Response: Superior B cell-depleting activity of type II anti-CD20 mAb is not due to activation of complement Blood, November 15, 2008; 112(10): 4355 - 4356. [Full Text] [PDF] |
||||
![]() |
A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, et al. Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities Cancer Res., May 15, 2008; 68(10): 3863 - 3872. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tawara, K. Hasegawa, Y. Sugiura, K. Harada, T. Miura, S. Hayashi, T. Tahara, M. Ishikawa, H. Yoshida, K. Kubo, et al. Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats J. Immunol., February 15, 2008; 180(4): 2294 - 2298. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. F. Dall'Acqua, K. E. Cook, M. M. Damschroder, R. M. Woods, and H. Wu Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region J. Immunol., July 15, 2006; 177(2): 1129 - 1138. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. van Meerten, R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. Clin. Cancer Res., July 1, 2006; 12(13): 4027 - 4035. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Lazar, W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. Engineered antibody Fc variants with enhanced effector function. PNAS, March 14, 2006; 103(11): 4005 - 4010. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Hinton, J. M. Xiong, M. G. Johlfs, M. T. Tang, S. Keller, and N. Tsurushita An Engineered Human IgG1 Antibody with Longer Serum Half-Life J. Immunol., January 1, 2006; 176(1): 346 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bang, L. Marnell, C. Mold, M.-P. Stein, K. T. D. Clos, C. Chivington-Buck, and T. W. D. Clos Analysis of Binding Sites in Human C-reactive Protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by Site-directed Mutagenesis J. Biol. Chem., July 1, 2005; 280(26): 25095 - 25102. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Carter and C. F. McDonagh Designer Antibody-Based Therapeutics for Oncology Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 147 - 154. [Full Text] [PDF] |
||||
![]() |
G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny From the bench to the bedside: ways to improve rituximab efficacy Blood, November 1, 2004; 104(9): 2635 - 2642. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship Cancer Res., July 1, 2004; 64(13): 4664 - 4669. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Kojouharova, M. G. Gadjeva, I. G. Tsacheva, A. Zlatarova, L. T. Roumenina, M. I. Tchorbadjieva, B. P. Atanasov, P. Waters, B. C. Urban, R. B. Sim, et al. Mutational Analyses of the Recombinant Globular Regions of Human C1q A, B, and C Chains Suggest an Essential Role for Arginine and Histidine Residues in the C1q-IgG Interaction J. Immunol., April 1, 2004; 172(7): 4351 - 4358. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Hong, R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross {beta}-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells Cancer Res., December 15, 2003; 63(24): 9023 - 9031. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gaboriaud, J. Juanhuix, A. Gruez, M. Lacroix, C. Darnault, D. Pignol, D. Verger, J. C. Fontecilla-Camps, and G. J. Arlaud The Crystal Structure of the Globular Head of Complement Protein C1q Provides a Basis for Its Versatile Recognition Properties J. Biol. Chem., November 21, 2003; 278(47): 46974 - 46982. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bannerji, S. Kitada, I. W. Flinn, M. Pearson, D. Young, J. C. Reed, and J. C. Byrd Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance J. Clin. Oncol., April 15, 2003; 21(8): 1466 - 1471. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Kennedy, M. D. Solga, T. A. Schuman, A. W. Chi, M. A. Lindorfer, W. M. Sutherland, P. L. Foley, and R. P. Taylor An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab Blood, February 1, 2003; 101(3): 1071 - 1079. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Shields, J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G. Meng, S. H. A. Weikert, and L. G. Presta Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-dependent Cellular Toxicity J. Biol. Chem., July 19, 2002; 277(30): 26733 - 26740. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene Blood, February 1, 2002; 99(3): 754 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Montano and S. L. Morrison Influence of the Isotype of the Light Chain on the Properties of IgG J. Immunol., January 1, 2002; 168(1): 224 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hezareh, A. J. Hessell, R. C. Jensen, J. G. J. van de Winkel, and P. W. H. I. Parren Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 J. Virol., December 15, 2001; 75(24): 12161 - 12168. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-K. Weng and R. Levy Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood, September 1, 2001; 98(5): 1352 - 1357. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Idusogie, P. Y. Wong, L. G. Presta, H. Gazzano-Santoro, K. Totpal, M. Ultsch, and M. G. Mulkerrin Engineered Antibodies with Increased Activity to Recruit Complement J. Immunol., February 15, 2001; 166(4): 2571 - 2575. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Shields, A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. High Resolution Mapping of the Binding Site on Human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fcgamma R J. Biol. Chem., February 23, 2001; 276(9): 6591 - 6604. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Vidarte, C. Pastor, S. Mas, A. B. Blazquez, V. de los Rios, R. Guerrero, and F. Vivanco Serine 132 Is the C3 Covalent Attachment Point on the CH1 Domain of Human IgG1 J. Biol. Chem., October 5, 2001; 276(41): 38217 - 38223. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |